AbbVie is now part of a growing group of companies that have turned to China to get a bispecific antibody designed to target PD-1 and VEGF to fight cancer. AbbVie may have more to say about the deal in its presentation this week during the annual J.P. Morgan Healthcare Conference in San Francisco.
Vor Bio is licensing global rights to a fusion protein that inhibits two targets to potentially treat the neuromuscular disorder generalized myasthenia gravis. It’s a pivot for Vor, which last month ceased its cancer R&D and announced it would explore strategic alternatives.
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.